These links are provided for information only. NPPG is not responsible for the content of any link
July 2020
- Patients with cystic fibrosis to have access to Kaftrio (ivacaftor/tezacaftor/elexacaftor) under deal between NHS and Vertex
- New product: Zolgensma (onasemnogene abeparvovec) 2 x 1013 vector genomes/mL solution for infusion
June 2020
- Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
- Multisystem Inflammatory Syndrome in Children in New York State
- European CHMP recommends approval of caffeine citrate (Gencebok) for treatment of primary apnoea of premature newborns
- Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic
- Childhood Trust report warns of serious mental health conditions in children due to COVID-19
- Gilead announces plans to study remdesivir in paediatric patients with COVID-19
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis
- FDA grants approval of dispersible tablet formulation of dolutegravir and extension of paediatric indication for HIV
- COVID-19 – ‘shielding’ guidance for children and young people updated
- Two-year results from ARC004, a follow-on study to phase 3 PALISADE trial of Palforzia (peanut allergen powder) in patients with peanut allergy
- Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis
- Intravenous fluid therapy in children and young people in hospital- updated guidance (NG29)
- Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
- COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
- Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
- Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
May 2020
- Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic
- Hyperinflammatory shock in children during COVID-19 pandemic
- DTB select: Dexamethasone or prednisolone for croup
- COVID-19 Guidance – Paediatric multisystem inflammatory syndrome temporally associated with COVID-19
- European CHMP recommends approval of wider use of ivacaftor in patients with cystic fibrosis and an R117H mutation in the CFTR gene
- European CHMP recommends approval of Harvoni (ledipasvir and sofosbuvir) for the treatment of paediatric patients with chronic hepatitis C
- COVID-19 rapid guideline: children and young people who are immunocompromised – guidance (NG174)
April 2020
- April BNF/BNFc Newsletter
- Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort
- Mental Health Status Among Children in Home Confinement During the Coronavirus Disease 2019 Outbreak in Hubei Province, China
- JCVI statement on immunisation prioritisation
- Can breastfeeding mothers take paracetamol or paracetamol combination products?
- Revised SPC: Revatio (sildenafil) preparations – risks outweigh benefits in PPH in newborn
- FDA approves selumetinib (Koselugo) for the treatment of children aged from 2 years with neurofibromatosis type 1
- NHS England Speciality Guide: Urgent and emergency musculoskeletal conditions in children (under 16) requiring onward referral
- Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group
- COVID-19 rapid guideline: cystic fibrosis- guideline (NG170)
- COVID-19 rapid guideline: severe asthma – guidance (NG166)
- National Patient Safety Alert: Interruption of high flow nasal oxygen during transfer
March 2020
- Paediatric to adult transition care for patients with sickle cell disease: a global perspective
- COVID-19: guidance on supporting children and young people’s mental health and wellbeing
- COVID-19 infection in children
- CHMP recommends licence extension for etravirine (Intelence)
- CHMP recommends licence extension for conestat alfa (Ruconest)
- US FDA accepts New Drug Application (NDA) for new formulation of baloxavir for the treatment of influenza in children
- Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
- Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn
- Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies
- Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study
- SARS-CoV-2 Infection in Children
- February BNF/BNFC newsletter
- Selumetinib in Children with Inoperable Plexiform Neurofibromas
- Clinical Commissioning Policy: Human coagulation factor X for hereditary factor X deficiency (all ages)
- Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
- Clinical Commissioning Policy: Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Clinical Commissioning Policy: Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages)
- Revised SPC: Dioralyte products
- New product: Adynovi (rurioctocog alfa pegol) 1000 IU powder and solvent for solution for injection 2 ml solvent
- Cardiovascular Health Trajectories From Childhood Through Middle Age and Their Association With Subclinical Atherosclerosis
- Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
- Clinical Commissioning Policy: Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Bronchiolitis: when less is more
- Import restrictions changed for cannabis-based medicines to allow faster access
- Ensuring access to safe, effective, and affordable cannabis‐based medicines
- State of Child Health in the UK
- FDA Grants rare paediatric disease designation for elamipretide for Barth Syndrome
- Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis A Systematic Review and Network Meta-analysis
- Canakinumab for Periodic Fever Syndromes in children to be commissioned by NHS England
February 2020
- Neonatal parenteral nutrition – guidance [NG154]
- Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study
- Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial
- Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial
- Plerixafor (Mozobil®) recommended for use within NHS Wales in combination with G-CSF
- New advances in the treatment of paediatric functional abdominal pain disorders
- Asthma: diagnosis, monitoring and chronic asthma management- updated guideline (NG80)
- Young people’s mental health and wellbeing research
- Refractory Epilepsy Specialist Clinical Advisory Service
- Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction
- A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents
- Lower versus Traditional Treatment Threshold for Neonatal Hypoglycemia
- US FDA approves Palforzia (Arachis hypogaea) Allergen Powder capsules for treatment of peanut allergy
January 2020
- Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of rituximab (MabThera) for paediatric patients
- Update on gender identity development service for children and young people
- First-Trimester Pregnancy Exposure to Modafinil and Risk of Congenital Malformations
- Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- US FDA approved fidaxomicin oral suspension for clostridioides difficile-associated diarrhoea (CDAD) in children aged six months and older
- Assessing coverage of interventions for reproductive, maternal, newborn, child, and adolescent health and nutrition
- European Medicines Agency approves license extension for ustekinumab to include treatment of plaque psoriasis in children between 6 and 11 years
- Duchenne muscular dystrophy (DMD)
- Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
- January BNF/BNFC Newsletter
- Where next for inhaled corticosteroids in childhood asthma?
- Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
- Sodium valproate Pregnancy Prevention Programme – updated Guide for Healthcare Professionals
- A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
- Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort
- Precocious puberty
- Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy
- Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial
- Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy
- Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen
For older news click here